Tag: UCB

January 6, 2017

Dermira Provides Corporate Update

Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of...
January 3, 2017

Dermira Initiates Phase 3 Clinical Program in Acne

Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of...
December 20, 2016

Neos Therapeutics Completes Resubmission of NDA for Cotempla XR-ODT for the Treatment of ADHD

Neos Therapeutics today announced that it has completed the resubmission of a New Drug Application (NDA) to the U.S. Food...
December 8, 2016

UCB and Dermira Announce Second CIMZIA® Phase 3 Trial Meets Co-Primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis

UCB and Dermira today announced topline results from CIMPASI-1, a Phase 3, multi-center, placebo-controlled clinical trial evaluating the efficacy and...
October 20, 2016

Evotec and UCB Sign Multi-Year CNS Pharmacology Agreement

Evotec today announced a collaboration with UCB to provide a broad range of in vitro pharmacology services.
October 10, 2016

Nicox Receives Complete Response from FDA Related for AC-170

Nicox,, the international ophthalmic R&D company, today announced that it has received a Complete Response Letter from the U.S. Food...
October 3, 2016

CIMZIA® Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis

UCB and Dermira today announced topline results from CIMPASI-2, a Phase 3, multi-center, placebo-controlled clinical trial evaluating the efficacy and...